AlphaMark Advisors’s Zymeworks ZYME Stock Holding History

AlphaMark Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,758	Closed	-$32K	–	833
2024 Q2	$32K	Buy	3,758 +754	+25%	+$6.71K	0.01%	389
2024 Q1	$32K	Buy	+3,004	New	+$33.4K	0.01%	392

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AlphaMark Advisors's ZYME Position: Q3 2024 in Review

AlphaMark Advisors sold out of Zymeworks (ZYME) in Q3 2024, closing a stake of 3,758 shares — an estimated $32K sold.

AlphaMark Advisors first reported a position in ZYME in Q1 2024 and held it in 2 quarters. The position peaked at $32K in Q2 2024. 163 funds tracked by Wall St. Rank hold ZYME as of Q3 2024.

AlphaMark Advisors reported no remaining Zymeworks position as of Q3 2024 after selling out during the quarter.
AlphaMark Advisors sold 3,758 Zymeworks shares in Q3 2024, an estimated $32K.
AlphaMark Advisors first reported a position in Zymeworks in Q1 2024 and held it in 2 quarters.
AlphaMark Advisors's Zymeworks position peaked at $32K in Q2 2024.
163 funds tracked by Wall St. Rank held Zymeworks as of Q3 2024.

Based on AlphaMark Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.